Nottingham Advisors’s Ocular Therapeutix OCUL Stock Holding History

Nottingham Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-33,083	Closed	-$242K	–	119
2025 Q1	$242K	Sell	33,083 -64,745	-66%	-$498K	0.04%	103
2024 Q4	$835K	Sell	97,828 -87,938	-47%	-$858K	0.11%	67
2024 Q3	$1.62M	Sell	185,766 -7,500	-4%	-$61.8K	0.18%	56
2024 Q2	$1.32M	Hold	193,266	–	–	0.16%	61
2024 Q1	$1.76M	Sell	193,266 -1,000	-0.5%	-$7.1K	0.22%	46
2023 Q4	$866K	Hold	194,266	–	–	0.12%	67
2023 Q3	$610K	Hold	194,266	–	–	0.09%	75
2023 Q2	$1M	Hold	194,266	–	–	0.13%	64
2023 Q1	$1.02M	Hold	194,266	–	–	0.14%	67
2022 Q4	$546K	Hold	194,266	–	–	0.07%	88
2022 Q3	$806K	Hold	194,266	–	–	0.12%	65
2022 Q2	$781K	Hold	194,266	–	–	0.11%	67
2022 Q1	$962K	Hold	194,266	–	–	0.11%	64
2021 Q4	$1.35M	Hold	194,266	–	–	0.15%	61
2021 Q3	$1.94M	Hold	194,266	–	–	0.19%	55
2021 Q2	$2.75M	Hold	194,266	–	–	0.31%	49
2021 Q1	$3.19M	Sell	194,266 -1,500	-0.8%	-$28.9K	0.36%	44
2020 Q4	$4.05M	Hold	195,766	–	–	0.59%	36
2020 Q3	$1.49M	Hold	195,766	–	–	0.19%	54
2020 Q2	$1.48K	Buy	195,766 +44,820	+30%	+$297K	0.09%	54
2020 Q1	$747K	Hold	150,946	–	–	0.11%	65
2019 Q4	$596K	Sell	150,946 -44,820	-23%	-$156K	0.08%	71
2019 Q3	$595K	Buy	195,766 +48,820	+33%	+$218K	0.08%	71
2019 Q2	$647K	Hold	146,946	–	–	0.09%	68
2019 Q1	$583K	Hold	146,946	–	–	0.08%	69
2018 Q4	$1.01M	Hold	146,946	–	–	0.15%	50
2018 Q3	$1.01M	Hold	146,946	–	–	0.15%	51
2018 Q2	$957K	Hold	146,946	–	–	0.15%	50
2018 Q1	$957K	Hold	146,946	–	–	0.16%	44
2017 Q4	$654K	Buy	146,946 +2,500	+2%	+$12.8K	0.09%	64
2017 Q3	$893K	Hold	144,446	–	–	0.13%	57
2017 Q2	$1.34M	Hold	144,446	–	–	0.2%	46
2017 Q1	$1.34M	Hold	144,446	–	–	0.21%	44
2016 Q4	$1.21M	Sell	144,446 -44,820	-24%	-$348K	0.21%	47
2016 Q3	$1.3M	Hold	189,266	–	–	0.23%	40
2016 Q2	$937K	Buy	189,266 +7,000	+4%	+$69.4K	0.17%	46
2016 Q1	$1.71M	Hold	182,266	–	–	0.32%	39
2015 Q4	$1.71M	Sell	182,266 -2,969	-2%	-$32.1K	0.32%	39
2015 Q3	$2.6M	Buy	185,235 +13,250	+8%	+$266K	0.47%	35
2015 Q2	$3.62M	Buy	171,985 +8,469	+5%	+$210K	0.6%	33
2015 Q1	$6.87M	Buy	+163,516	New	+$5.38M	1.13%	27

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Nottingham Advisors's OCUL Position: Q2 2025 in Review

Nottingham Advisors sold out of Ocular Therapeutix (OCUL) in Q2 2025, closing a stake of 33,083 shares — an estimated $242K sold.

Nottingham Advisors first reported a position in OCUL in Q1 2015 and held it in 41 quarters. The position peaked at $6.87M in Q1 2015. 186 funds tracked by Wall St. Rank hold OCUL as of Q2 2025.

Nottingham Advisors reported no remaining Ocular Therapeutix position as of Q2 2025 after selling out during the quarter.
Nottingham Advisors sold 33,083 Ocular Therapeutix shares in Q2 2025, an estimated $242K.
Nottingham Advisors first reported a position in Ocular Therapeutix in Q1 2015 and held it in 41 quarters.
Nottingham Advisors's Ocular Therapeutix position peaked at $6.87M in Q1 2015.
186 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2025.

Based on Nottingham Advisors's 13F filing for Q2 2025, filed 30 Jul 2025.